A Travesty at the FDA

Update 2021-08-20 since this is getting more attention: Shortly after I wrote this post, the FDA backtracked a bit, and restricted the indication to only early-stage Alzheimer’s patients. This means that it’s unlikely aducanumab will cost $100 billion per year. Still, it could be extremely expensive.

Read →